Registration Now Open for NPE2024: The Plastics Show
12.9.2023 19:34:00 EEST | Business Wire | Press release
The Plastics Industry Association (PLASTICS) announced today that NPE2024: The Plastics Show registrations are now open through May 2024. NPE2024 will be the most impactful trade show of the year for all plastics industry sectors in the U.S. and globally, with more than 55,000 attendees expected.
Every three years, NPE offers the plastics industry a global platform to highlight innovation across a show floor with more than 1.1 million net square feet of exhibit space at the Orange County Convention Center in Orlando, Fla. Matt Seaholm, President and CEO of PLASTICS, highlighted that NPE2024 will return bigger and better than ever, “We look forward to welcoming our industry back to NPE2024: The Plastics Show next May. The plastic industry serves a critical and sustainable role in modern life; this show will be a testament to that.”
“With sustainability at the center of everything produced at the show, attendees will witness new technologies and significant education opportunities to push us toward a more circular economy and help our industry continue to grow,” said Seaholm.
NPE2024 returns, with the theme Made for You, where attendees are front and center of all experiences happening at the show. The event, held May 6-10, 2024, will offer opportunities for everyone in the industry, even those just starting their career. Some notable experiences at NPE2024 include:
- Six technology zones with 2,000+ exhibitors showcasing their latest products and services
- More than 100 speaker presentations on trending topics that foster innovation, drive circularity and exemplify collaboration
- The brand-new NPE Circularity Hub where attendees will experience the plastics circular economy, from raw materials to go-to market consumer products
- Influential women in the plastics industry will share their success stories with those attending the Women in Plastics Breakfast
- More than 355 first-time exhibitors bringing to NPE2024 new products and perspectives
- The inaugural NPE Opening Night Party featuring the band Pop Rocks, games, food and drinks
NPE2024 attendees will gain exclusive access to the entire plastics supply chain, including machinery and equipment, raw materials, recycling and sustainability, automation and robotics, 3D and 4D printing, inspection, design, and more. NPE exhibitors service vital markets such as automotive, consumer products, recycling, packaging, medical, and building and construction.
Important dates to remember if planning on attending NPE2024:
- Attendee registration for NPE2024 opens on Tuesday, September 12, 2023
- Registration for the hotel room block also begins on Tuesday, September 12, 2023
- NPE2024 event dates are May 6-10, 2024, at the Orange County Convention Center in Orlando, Fla.
Tickets for NPE2024 range from $100 - $600; prices vary depending on early bird, advanced and on-site sales. Add-ons to the NPE Opening Night Party, Women in Plastics Breakfast, Seminarios Latinoamericanos, and 3D Printing for Plastic Processors are also available on a first-come, first-served basis, inquire for details.
“NPE2024 is at the forefront of the plastics future. If you want to further your career, grow your company or keep up with new trends and solutions, NPE2024 is where you need to be in May 2024. We encourage you to register today and start planning and customizing your experience as we continue to reveal all the exciting things happening at the event,” concluded Steve London, NPE2024 Committee Chair.
For more information about NPE2024: The Plastics Show and to register, visit: NPE.org.
The Plastics Industry Association (PLASTICS) is the only organization that supports the entire plastics supply chain, including Equipment Suppliers, Material Suppliers, Processors, and Recyclers, representing over one million workers in our $548 billion U.S. industry. PLASTICS advances the priorities of our members who are dedicated to investing in technologies that improve capabilities and advances in recycling and sustainability and providing essential products that allow for the protection and safety of our lives. Since 1937, PLASTICS has been working to make its members, and the seventh largest U.S. manufacturing industry, more globally competitive while supporting circularity through educational initiatives, industry-leading insights and events, convening opportunities and policy advocacy, including the largest plastics trade show in the Americas, NPE2024: The Plastics Show.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911029303/en/
Contact information
Elizabeth Domenech pr@npe.org
Camille Gallo cgallo@plasticsindustry.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
